1. Chiowchanwisawakit, P, Orawongpaisarn, A, Katchamart, W. Construct validity, reliability, and threshold value for treatment goals of the Thai version of the 12-item Psoriatic Arthritis Impact of Disease Questionnaire for patients with psoriatic arthritis. Int J Rheum Dis. 2024;27 (4):e15139. doi: 10.1111/1756-185X.15139. PubMed PMID:38610096 .
  2. Yoshida, A, Li, Y, Maroufy, V, Kuwana, M, Sazliyana Shaharir, S, Makol, A et al.. Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey. Rheumatol Adv Pract. 2024;8 (2):rkae028. doi: 10.1093/rap/rkae028. PubMed PMID:38524696 PubMed Central PMC10960935.
  3. Santos, CS, Chen, JP, Nikiphorou, E, Tseng, CW, Gutiérrez, CET, Tan, AL et al.. Breakthrough SARS-CoV-2 infection and disease flares in patients with rheumatoid arthritis: result from COVAD e-survey study. Rheumatol Int. 2024;44 (5):805-817. doi: 10.1007/s00296-024-05542-3. PubMed PMID:38470502 .
  4. Hoff, LS, Naveen, R, Sen, P, Day, J, Joshi, M, Nune, A et al.. Characteristics and risk factors of COVID-19 breakthrough infections in Idiopathic Inflammatory Myopathies: Results from the COVAD study. Rheumatology (Oxford). 2024; :. doi: 10.1093/rheumatology/keae128. PubMed PMID:38430474 .
  5. Dey, M, Doskaliuk, B, Lindblom, J, Nikiphorou, E, Wincup, C, Fathima, M et al.. COVID-19 Vaccination-Related Delayed Adverse Events among Patients with Systemic Lupus Erythematosus. J Clin Med. 2023;12 (24):. doi: 10.3390/jcm12247542. PubMed PMID:38137611 PubMed Central PMC10743599.
  6. Panchawagh, S, Ravichandran, N, Barman, B, Nune, A, Javaid, M, Gracia-Ramos, AE et al.. COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group. Rheumatol Int. 2024;44 (1):73-80. doi: 10.1007/s00296-023-05496-y. PubMed PMID:38060005 PubMed Central PMC10766674.
  7. Sandhu, NK, Ravichandraan, N, Nune, A, Day, J, Sen, P, Nikiphorou, E et al.. Flares of autoimmune rheumatic disease following COVID-19 infection: Observations from the COVAD study. Int J Rheum Dis. 2024;27 (1):e14961. doi: 10.1111/1756-185X.14961. PubMed PMID:37969016 .
  8. Panchawagh, S, Bohdana, D, Kuwana, M, Yoshida, A, Yomono, K, Pauling, JD et al.. Delayed adverse events following COVID-19 vaccination in patients with systemic sclerosis and other autoimmune diseases: a substudy of the COVAD-2 cohort. Rheumatol Int. 2023;43 (12):2211-2220. doi: 10.1007/s00296-023-05441-z. PubMed PMID:37712977 .
  9. Andreoli, L, Lini, D, Schreiber, K, Parodis, I, Sen, P, Naveen, R et al.. COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study. Rheumatology (Oxford). 2023; :. doi: 10.1093/rheumatology/kead382. PubMed PMID:37505460 .
  10. Doskaliuk, B, Ravichandran, N, Sen, P, Day, J, Joshi, M, Nune, A et al.. Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study. Rheumatol Int. 2023;43 (9):1651-1664. doi: 10.1007/s00296-023-05345-y. PubMed PMID:37351634 PubMed Central PMC10348925.
  11. Katchamart, W, Kieattisaksopon, S, Narongroeknawin, P, Muangpaisan, W, Varothai, N. Risk Factors for Sarcopenia in Thai Patients with Rheumatoid Arthritis. Discov Med. 2023;35 (176):436-443. doi: 10.24976/Discov.Med.202335176.44. PubMed PMID:37272110 .
  12. Prawjaeng, J, Leelahavarong, P, Budtarad, N, Pilasant, S, Chanjam, C, Katchamart, W et al.. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity. BMC Health Serv Res. 2023;23 (1):561. doi: 10.1186/s12913-023-09595-1. PubMed PMID:37259090 PubMed Central PMC10230705.
  13. R, N, Sen, P, Griger, Z, Day, J, Joshi, M, Nune, A et al.. Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveys. Rheumatology (Oxford). 2024;63 (1):127-139. doi: 10.1093/rheumatology/kead180. PubMed PMID:37084267 .
  14. Ali, SS, R, N, Sen, P, Day, J, Joshi, M, Nune, A et al.. Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study. Rheumatology (Oxford). 2023;62 (9):e263-e268. doi: 10.1093/rheumatology/kead149. PubMed PMID:37004201 .
  15. Jagtap, K, Naveen, R, Day, J, Sen, P, Vaidya, B, Nune, A et al.. Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period-a cross-sequential study based on COVAD surveys. Rheumatology (Oxford). 2023;62 (12):3838-3848. doi: 10.1093/rheumatology/kead144. PubMed PMID:36961331 .
  16. Sen, P, R, N, Houshmand, N, Moghadam Kia, S, Joshi, M, Saha, S et al.. Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys. Rheumatology (Oxford). 2023;62 (10):3291-3301. doi: 10.1093/rheumatology/kead057. PubMed PMID:36734536 .
  17. Katchamart, W, Ngamjanyaporn, P, Orawongpaisarn, A, Phubangkertphon, T, Borrirukwisitsak, S, Dechapaphapitak, N et al.. Real world safety of CT-P10 (anti-CD 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases. BMC Rheumatol. 2022;6 (1):77. doi: 10.1186/s41927-022-00306-7. PubMed PMID:36447248 PubMed Central PMC9710159.
  18. Andreoli, L, Sen, P, Lini, D, Vincze, MN, Schreiber, K, Agarwal, V et al.. COVID-19 vaccine safety during the antenatal period in women with idiopathic inflammatory myopathies. Rheumatology (Oxford). 2023;62 (6):e175-e179. doi: 10.1093/rheumatology/keac644. PubMed PMID:36370070 .
  19. Panichaporn, S, Chanapai, W, Srisomnuek, A, Thaweeratthakul, P, Katchamart, W. Validity and Reliability of the Thai Version of the 19-Item Compliance-Questionnaire-Rheumatology. Patient Prefer Adherence. 2022;16 :2149-2158. doi: 10.2147/PPA.S374445. PubMed PMID:36003800 PubMed Central PMC9393110.
  20. Fazal, ZZ, Sen, P, Joshi, M, Ravichandran, N, Lilleker, JB, Agarwal, V et al.. COVAD survey 2 long-term outcomes: unmet need and protocol. Rheumatol Int. 2022;42 (12):2151-2158. doi: 10.1007/s00296-022-05157-6. PubMed PMID:35964271 PubMed Central PMC9376047.
  21. Chokevittaya, P, Chayakulkeeree, M, Katchamart, W. Risk Factors, Clinical Characteristics, Management, and Outcomes of Musculoskeletal Fungal Infection at Thailand's Largest National Tertiary Referral Center. J Fungi (Basel). 2022;8 (2):. doi: 10.3390/jof8020191. PubMed PMID:35205946 PubMed Central PMC8880593.
  22. Ytterberg, SR, Bhatt, DL, Mikuls, TR, Koch, GG, Fleischmann, R, Rivas, JL et al.. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386 (4):316-326. doi: 10.1056/NEJMoa2109927. PubMed PMID:35081280 .
  23. Sun, X, Li, R, Cai, Y, Al-Herz, A, Lahiri, M, Choudhury, MR et al.. Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. Lancet Reg Health West Pac. 2021;15 :100240. doi: 10.1016/j.lanwpc.2021.100240. PubMed PMID:34528015 PubMed Central PMC8365438.
  24. Borrirukwisitsak, S, Tantayakom, P, Katchamart, W. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis. Clin Rheumatol. 2021;40 (7):2779-2789. doi: 10.1007/s10067-020-05542-1. PubMed PMID:33428098 .
  25. Katchamart, W, Narongroeknawin, P, Sukprasert, N, Chanapai, W, Srisomnuek, A. Rate and causes of noncompliance with disease-modifying antirheumatic drug regimens in patients with rheumatoid arthritis. Clin Rheumatol. 2021;40 (4):1291-1298. doi: 10.1007/s10067-020-05409-5. PubMed PMID:32955630 .
  26. Phaopraphat, K, Ngamjanyaporn, P, Narongroeknawin, P, Kasitanon, N, Katchamart, W. Clinical manifestations, clinical course, and outcomes of immunoglobulin G4-related disease. Int J Rheum Dis. 2020;23 (11):1468-1473. doi: 10.1111/1756-185X.13949. PubMed PMID:32808722 .
  27. Katchamart, W, Narongroeknawin, P, Chanapai, W, Thaweeratthakul, P, Srisomnuek, A. Prevalence of and factors associated with depression and anxiety in patients with rheumatoid arthritis: A multicenter prospective cross-sectional study. Int J Rheum Dis. 2020;23 (3):302-308. doi: 10.1111/1756-185X.13781. PubMed PMID:31908153 .
  28. Katchamart, W, Narongroeknawin, P, Suppa-Udom, B, Chanapai, W, Srisomnuek, A. Factors associated with and cutoff points for Patient Acceptable Symptom State (PASS) in rheumatoid arthritis. Clin Rheumatol. 2020;39 (3):779-786. doi: 10.1007/s10067-019-04860-3. PubMed PMID:31823142 .
  29. Yongchairat, K, Tanboon, J, Waisayarat, J, Narongroeknawin, P, Chevaisrakul, P, Dejthevaporn, C et al.. Clinical spectrums and outcomes of necrotizing autoimmune myopathy versus other idiopathic inflammatory myopathies: a multicenter case-control study. Clin Rheumatol. 2019;38 (12):3459-3469. doi: 10.1007/s10067-019-04756-2. PubMed PMID:31446540 .
  30. Katchamart, W, Narongroeknawin, P, Chanapai, W, Thaweeratthakul, P. Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol. 2019;3 :34. doi: 10.1186/s41927-019-0080-9. PubMed PMID:31428740 PubMed Central PMC6694487.
  31. Napaumpaiporn, C, Katchamart, W. Clinical manifestations and outcomes of musculoskeletal nontuberculous mycobacterial infections. Rheumatol Int. 2019;39 (10):1783-1787. doi: 10.1007/s00296-019-04392-8. PubMed PMID:31352560 .
  32. Katchamart, W, Narongroeknawin, P, Phutthinart, N, Srinonprasert, V, Muangpaisan, W, Chaiamnauy, S et al.. Disease activity is associated with cognitive impairment in patients with rheumatoid arthritis. Clin Rheumatol. 2019;38 (7):1851-1856. doi: 10.1007/s10067-019-04488-3. PubMed PMID:30848400 .
  33. Chiowchanwisawakit, P, Srinonprasert, V, Thaweeratthakul, P, Katchamart, W. Disease activity and functional status associated with health-related quality of life and patient-acceptable symptom state in patients with psoriatic arthritis in Thailand: A cross-sectional study. Int J Rheum Dis. 2019;22 (4):700-707. doi: 10.1111/1756-185X.13473. PubMed PMID:30666824 .
  34. Phuan-Udom, R, Lektrakul, N, Katchamart, W. The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis. Clin Rheumatol. 2018;37 (10):2603-2610. doi: 10.1007/s10067-018-4218-8. PubMed PMID:30039267 .
  35. Ruangpin, C, Rodchuae, M, Katchamart, W. Factors Related to Surgical Treatment and Outcomes of Thai Patients With Septic Arthritis. J Clin Rheumatol. 2019;25 (4):176-180. doi: 10.1097/RHU.0000000000000826. PubMed PMID:29912769 .
  36. Chiowchanwisawakit, P, Katchamart, W, Osiri, M, Narongroeknawin, P, Chevaisrakul, P, Kitumnuaypong, T et al.. Effectiveness and Drug Survival of Anti-Tumor Necrosis Factor α Therapies in Patients With Spondyloarthritis: Analysis From the Thai Rheumatic Disease Prior Authorization Registry. J Clin Rheumatol. 2019;25 (1):9-15. doi: 10.1097/RHU.0000000000000741. PubMed PMID:29517554 .
  37. Chiowchanwisawakit, P, Thaweeratthakul, P, Wattanamongkolsil, L, Srinonprasert, V, Koolvisoot, A, Muangchan, C et al.. Relationship Between Health-Related Quality of Life and Patient Acceptable Symptom State With Disease Activity and Functional Status in Patients With Ankylosing Spondylitis in Thailand. J Clin Rheumatol. 2019;25 (1):16-23. doi: 10.1097/RHU.0000000000000750. PubMed PMID:29509563 .
  38. Narongroeknawin, P, Chevaisrakul, P, Kasitanon, N, Kitumnuaypong, T, Mahakkanukrauh, A, Siripaitoon, B et al.. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry. Int J Rheum Dis. 2018;21 (1):170-178. doi: 10.1111/1756-185X.12937. PubMed PMID:28737837 .
  39. Louthrenoo, W, Kasitanon, N, Katchamart, W, Aiewruengsurat, D, Chevaisrakul, P, Chiowchanwisawakit, P et al.. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Int J Rheum Dis. 2017;20 (9):1166-1184. doi: 10.1111/1756-185X.13130. PubMed PMID:28730640 .
  40. Rodchuae, M, Ruangpin, C, Katchamart, W. Clinical manifestations, treatment outcomes, and risk factors for sternoclavicular septic arthritis. Rheumatol Int. 2017;37 (5):819-824. doi: 10.1007/s00296-017-3673-x. PubMed PMID:28239769 .
  41. Teerawattananon, C, Tantayakom, P, Suwanawiboon, B, Katchamart, W. Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: A systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46 (4):520-528. doi: 10.1016/j.semarthrit.2016.07.008. PubMed PMID:27569276 .
  42. Katchamart, W, Narongroeknawin, P, Chevaisrakul, P, Dechanuwong, P, Mahakkanukrauh, A, Kasitanon, N et al.. Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association. Int J Rheum Dis. 2017;20 (9):1142-1165. doi: 10.1111/1756-185X.12905. PubMed PMID:27452207 .
  43. Chiowchanwisawakit, P, Wattanamongkolsil, L, Srinonprasert, V, Petcharat, C, Siriwanarangsun, P, Katchamart, W et al.. Developing the Thai Siriraj Psoriatic Arthritis Screening Tool and validating the Thai Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaire. Rheumatol Int. 2016;36 (10):1459-68. doi: 10.1007/s00296-016-3513-4. PubMed PMID:27333800 .
  44. Tantayakom, P, Koolvisoot, A, Arromdee, E, Chiowchanwisawakit, P, Muangchan, C, Katchamart, W et al.. Metabolic syndrome is associated with disease activity in patients with rheumatoid arthritis. Joint Bone Spine. 2016;83 (5):563-7. doi: 10.1016/j.jbspin.2015.10.016. PubMed PMID:27238198 .
  45. Katchamart, W, Koolvisoot, A, Aromdee, E, Chiowchanwesawakit, P, Muengchan, C. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatol Int. 2015;35 (10):1693-9. doi: 10.1007/s00296-015-3271-8. PubMed PMID:25903353 .
  46. Buppajamrntham, T, Palavutitotai, N, Katchamart, W. Clinical manifestation, diagnosis, management, and treatment outcome of pericarditis in patients with systemic lupus erythematosus. J Med Assoc Thai. 2014;97 (12):1234-40. . PubMed PMID:25764628 .
  47. Palavutitotai, N, Buppajarntham, T, Katchamart, W. Etiologies and outcomes of pleural effusions in patients with systemic lupus erythematosus. J Clin Rheumatol. 2014;20 (8):418-21. doi: 10.1097/RHU.0000000000000179. PubMed PMID:25417677 .
  48. Chaisurote, J, Khemajira, K, Wanwisa, C, Katchamart, W. Validation of the Thai version of the questionnaire for identifying subjects with potential rheumatic diseases. J Med Assoc Thai. 2014;97 (3):308-16. . PubMed PMID:25123010 .
  49. Lee, EB, Fleischmann, R, Hall, S, Wilkinson, B, Bradley, JD, Gruben, D et al.. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370 (25):2377-86. doi: 10.1056/NEJMoa1310476. PubMed PMID:24941177 .
  50. Shea, B, Swinden, MV, Ghogomu, ET, Ortiz, Z, Katchamart, W, Rader, T et al.. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014;41 (6):1049-60. doi: 10.3899/jrheum.130738. PubMed PMID:24737913 .
  51. Katchamart, W, Benjamanukul, S, Chiowchanwesawakit, P. Validation of the Thai version of the Health Assessment Questionnaire for patients with psoriatic arthritis. Int J Rheum Dis. 2014;17 (2):181-5. doi: 10.1111/1756-185X.12215. PubMed PMID:24618364 .
  52. Rojanasantikul, P, Pattrapornpisut, P, Anuruckparadorn, K, Katchamart, W. The performance of a point of care test for detection of anti-mutated citrullinated vimentin and rheumatoid factor in early rheumatoid arthritis. Clin Rheumatol. 2014;33 (7):919-23. doi: 10.1007/s10067-014-2544-z. PubMed PMID:24577818 .
  53. Shea, B, Swinden, MV, Tanjong Ghogomu, E, Ortiz, Z, Katchamart, W, Rader, T et al.. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;2013 (5):CD000951. doi: 10.1002/14651858.CD000951.pub2. PubMed PMID:23728635 PubMed Central PMC7046011.
  54. Chiowchanwisawakit, P, Taweesuk, A, Katchamart, W, Srinonprasert, V. Prevalence and risk factors of symptomatic hyperuricemia; quality of care of patients with hyperuricemia in a university hospital. J Med Assoc Thai. 2013;96 Suppl 2 :S178-86. . PubMed PMID:23590040 .
  55. Katchamart, W, Ussavasodhi, P, Chiowchanwesawakit, P, Chanapai, W. Cross-cultural adaptation and validation of the Thai version of the Rheumatoid Arthritis Disease Activity Index (RADAI). Rheumatol Int. 2013;33 (10):2503-8. doi: 10.1007/s00296-013-2749-5. PubMed PMID:23588410 .
  56. Katchamart, W. Reply to the letter regarding "Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis". J Gastroenterol. 2013;48 (5):675. doi: 10.1007/s00535-013-0786-1. PubMed PMID:23494647 .
  57. Chiowchanwisawakit, P, Nilganuwong, S, Srinonprasert, V, Boonprasert, R, Chandranipapongse, W, Chatsiricharoenkul, S et al.. Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy. Int J Rheum Dis. 2013;16 (1):47-55. doi: 10.1111/1756-185X.12029. PubMed PMID:23441772 .
  58. Chadchavalpanichaya, N, Katchamart, W, Charatrungolan, T, Nualnim, P. The efficacy of adjustable toe splint on decreasing metatarsalgia in patients with lesser toe deformity: a prospective, randomized single-blinded controlled trial. J Med Assoc Thai. 2012;95 (12):1575-82. . PubMed PMID:23390790 .
  59. Jarupongprapa, S, Ussavasodhi, P, Katchamart, W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol. 2013;48 (7):830-8. doi: 10.1007/s00535-012-0717-6. PubMed PMID:23208017 .
  60. Chiowchanwisawakit, P, Srinonprasert, V, Nilganuwong, S, Katchamart, W, Koolvisoot, A, Arromdee, E et al.. Antimalarial-induced maculopathy: accuracy of Amsler grid as a diagnostic tool and risk factors. J Med Assoc Thai. 2012;95 Suppl 2 :S218-26. . PubMed PMID:22574553 .
  61. Salliot, C, Finckh, A, Katchamart, W, Lu, Y, Sun, Y, Bombardier, C et al.. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis. 2011;70 (2):266-71. doi: 10.1136/ard.2010.132134. PubMed PMID:21097801 .
  62. Katchamart, W, Faulkner, A, Feldman, B, Tomlinson, G, Bombardier, C. PubMed had a higher sensitivity than Ovid-MEDLINE in the search for systematic reviews. J Clin Epidemiol. 2011;64 (7):805-7. doi: 10.1016/j.jclinepi.2010.06.004. PubMed PMID:20926257 .
  63. Machado, P, Castrejon, I, Katchamart, W, Koevoets, R, Kuriya, B, Schoels, M et al.. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2011;70 (1):15-24. doi: 10.1136/ard.2010.130625. PubMed PMID:20724311 PubMed Central PMC3002765.
  64. Katchamart, W, Bourré-Tessier, J, Donka, T, Drouin, J, Rohekar, G, Bykerk, VP et al.. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J Rheumatol. 2010;37 (7):1422-30. doi: 10.3899/jrheum.090978. PubMed PMID:20516029 .
  65. Katchamart, W, Bombardier, C. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis. J Rheumatol. 2010;37 (7):1411-5. doi: 10.3899/jrheum.090980. PubMed PMID:20436069 .
  66. Katchamart, W, Trudeau, J, Phumethum, V, Bombardier, C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev. 2010;2010 (4):CD008495. doi: 10.1002/14651858.CD008495. PubMed PMID:20393970 PubMed Central PMC8946299.
  67. Katchamart, W, Johnson, S, Lin, HJ, Phumethum, V, Salliot, C, Bombardier, C et al.. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken). 2010;62 (8):1128-43. doi: 10.1002/acr.20188. PubMed PMID:20235210 .
  68. Katchamart, W, Trudeau, J, Phumethum, V, Bombardier, C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68 (7):1105-12. doi: 10.1136/ard.2008.099861. PubMed PMID:19054823 PubMed Central PMC2689526.
  69. Visser, K, Katchamart, W, Loza, E, Martinez-Lopez, JA, Salliot, C, Trudeau, J et al.. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68 (7):1086-93. doi: 10.1136/ard.2008.094474. PubMed PMID:19033291 PubMed Central PMC2689523.
Search PubMed